STOCK TITAN

Atossa Therapeutics (ATOS) Stock Price, News & Analysis

ATOS NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
73 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-41.2% close of June 11, 2026
1-year change
-85.9% closing prices, November 20, 2025 to November 20, 2026
1-month change
-37.2% closing prices, October 20, 2026 to November 20, 2026

Company Description

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company focused on developing medicines in oncology and other areas of significant unmet medical need. Recent company communications consistently describe Atossa as concentrating on therapies for breast cancer and broader oncology indications, while also exploring opportunities in rare diseases.

The company’s work centers on its lead product candidate, (Z)-Endoxifen, an investigational, proprietary oral formulation of endoxifen. Atossa describes (Z)-Endoxifen as a highly potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with activity across multiple mechanisms of interest. According to Atossa, its formulation is designed to deliver ER-targeted effects and inhibit protein kinase C beta 1 (PKCβ1), a known oncogenic signaling pathway, at clinically achievable concentrations. Atossa states that (Z)-Endoxifen is not approved for any indication.

Core development focus: breast cancer and breast conditions

Across multiple press releases, Atossa highlights a strategy to develop (Z)-Endoxifen across the breast cancer continuum of care, including:

  • Metastatic breast cancer (mBC): Atossa has described a planned dose-ranging study of (Z)-Endoxifen monotherapy in women with metastatic breast cancer, intended to evaluate safety, pharmacokinetics/pharmacodynamics, and preliminary anti-tumor activity and to inform potential later-stage trials.
  • Neoadjuvant ER+/HER2- breast cancer: The company is advancing the Phase 2 EVANGELINE trial, a randomized neoadjuvant study in premenopausal women with ER+/HER2- breast cancer. Atossa reports that this trial evaluates (Z)-Endoxifen with ovarian function suppression compared with an aromatase inhibitor-based regimen, with endpoints that include Ki-67 proliferation markers, safety, and imaging-based tumor response.
  • Breast cancer risk reduction and mammographic breast density: Atossa discusses a low-dose (Z)-Endoxifen strategy aimed at reducing mammographic breast density and, more broadly, breast cancer risk in high-risk women. The company has engaged with the U.S. Food and Drug Administration (FDA) through a Type C meeting request to discuss a regulatory strategy for low-dose (Z)-Endoxifen in breast cancer risk reduction.
  • Ductal carcinoma in situ (DCIS) and active surveillance: Atossa participates in the RECAST DCIS platform trial, a multi-arm Phase 2 study sponsored by Quantum Leap Healthcare Collaborative. In this trial, (Z)-Endoxifen is one of several endocrine agents being evaluated in hormone receptor–positive DCIS to help identify which patients may be appropriate for active surveillance rather than surgery, using imaging and biomarker endpoints.

Through these programs, Atossa positions (Z)-Endoxifen as a candidate for use in metastatic, neoadjuvant, risk-reduction, and early non-invasive breast disease settings. Company materials emphasize the potential to personalize endocrine therapy and expand options for patients who may not tolerate or respond to existing hormonal treatments.

Expansion into rare diseases and additional oncology indications

In addition to breast cancer, Atossa has disclosed efforts to evaluate (Z)-Endoxifen in other serious conditions:

  • Duchenne Muscular Dystrophy (DMD): The FDA has granted Rare Pediatric Disease (RPD) designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy. Atossa notes that RPD designation is reserved for serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age and may qualify a sponsor for a Priority Review Voucher upon approval of a qualifying application. Company communications describe a mechanistic rationale for (Z)-Endoxifen in DMD, including modulation of estrogen receptors, PKCβ1, and other signaling pathways, and discuss its potential role as an adjunct to standard care and as a mutation-agnostic approach.
  • Duchenne carrier–associated pathologies (D-CAPs): Atossa has highlighted scientific work exploring (Z)-Endoxifen in symptomatic female carriers of DMD, noting that a subset of carriers experience skeletal muscle symptoms and cardiomyopathy. The company references a hypothesis article and a scientific presentation focused on how (Z)-Endoxifen’s pharmacology could be relevant in this population.
  • Glioblastoma multiforme (GBM): In collaboration with Insilico Medicine, Atossa co-authored an AI-driven study published in Nature’s Scientific Reports that identified (Z)-Endoxifen as a potential therapeutic candidate for glioblastoma. Using Insilico’s PandaOmics platform, the study evaluated more than 900 cancer indications and ranked GBM as a high-opportunity indication based on transcriptomic and multi-omic analyses. The publication reports that (Z)-Endoxifen suppressed GBM cell proliferation in vitro and was well tolerated in in vivo models, supporting further investigation.

Atossa also references exploratory work in other hormone-driven and estrogen-related conditions, as well as rare diseases, while maintaining that oncology—particularly breast cancer—remains its core focus.

Intellectual property and formulation strategy

Atossa emphasizes a growing global intellectual property portfolio around (Z)-Endoxifen. The company reports multiple issued U.S. patents and corresponding applications worldwide covering:

  • Enteric oral formulations of highly pure (Z)-Endoxifen free base
  • Methods for making and using endoxifen in hormone-dependent breast disorders and other estrogen-related conditions
  • Stable crystalline forms and sustained-release formulations
  • Manufacturing methods and dosage forms designed to provide sustained systemic exposure

According to Atossa, its proprietary enteric oral formulation is designed to bypass stomach acid to help maintain the active Z-isomer and minimize conversion to the inactive E-form. Company disclosures state that clinical studies to date have shown favorable tolerability in healthy volunteers and breast cancer patients across a range of doses, and that no maximum tolerated dose has been identified in the studied range. Atossa presents this formulation and IP position as central to its long-term strategy for potential commercialization and exclusivity if (Z)-Endoxifen is approved.

Regulatory interactions and development strategy

Atossa reports frequent engagement with the FDA to shape its development path. Recent updates include:

  • A Type C meeting with the FDA to discuss expedited regulatory pathways and development options for (Z)-Endoxifen across metastatic breast cancer, neoadjuvant treatment, and breast cancer risk reduction.
  • An FDA “Study May Proceed” letter for an investigational new drug (IND) application covering a study of (Z)-Endoxifen in metastatic ER+/HER2- breast cancer.
  • Plans and interactions related to IND submissions for metastatic breast cancer and potential combination strategies, as described in company press releases.

Atossa’s communications describe a strategy that emphasizes disciplined capital allocation, focusing resources on programs and data packages that could support future regulatory submissions, including potential New Drug Applications (NDAs), and eventual commercialization if approvals are obtained.

Listing status and exchange information

Atossa’s common stock trades on Nasdaq under the ticker symbol ATOS. In an 8-K filing, the company disclosed that it received a Nasdaq notice regarding non-compliance with the minimum bid price requirement and that Nasdaq granted an extension of the deadline to regain compliance. The filing states that the notice had no immediate effect on the listing or trading of the company’s common stock and that Atossa is considering available options, including a potential reverse stock split, to address the requirement.

Business model characteristics

Based on its public disclosures, Atossa operates as a clinical-stage biopharmaceutical developer. The company indicates that it does not have approved products and is investing in research and development for (Z)-Endoxifen across multiple indications. Its communications highlight clinical trial execution, regulatory strategy, and intellectual property protection as key elements of its approach. Financial disclosures in recent 8-K filings show operating expenses primarily related to research and development and general and administrative functions, with (Z)-Endoxifen identified as the only product candidate for which the company currently incurs R&D expenses.

Risk profile and development stage

Atossa’s own press releases and SEC filings characterize it as being in the clinical development phase, with multiple ongoing and planned trials but no approved therapies. As with many clinical-stage biopharmaceutical companies, outcomes depend on the success of clinical studies, regulatory feedback, and the strength and duration of its intellectual property. The company’s disclosures also note typical sector risks, such as patent challenges and the need to maintain exchange listing standards.

Stock Performance

$1.65
+3.45%
+0.05
After hoursChange vs the $1.60 closeLast updated: at
-85.9%
Performance 1 year
$16.5M

Atossa Therapeutics (ATOS) closed at $1.60 on November 20, 2026. Over the past 12 months, the price has lost 85.9%.

See what a $1,000 investment in ATOS would be worth today

Average down calculator for ATOS

ATOS Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Atossa Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, offering. View all ATOS news →

Financial Highlights

Atossa Therapeutics reported operating income of -$37.1M in FY2025, and net income was -$34.8M. Diluted earnings per share stood at -$4.04. The company generated -$29.8M in operating cash flow. The current ratio was 5.53, measuring current assets divided by current liabilities.

-$34.8M
Net Income (FY2025)
-$29.8M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
2026
December 2026 Marketing

Data Presentations

Company plans data presentations for Karisma and I-SPY2 arm enrollment in December 2026; venue/webcast TBD.
YEAR
2027
2027 Regulatory

FDA Clearances

Atossa expects FDA clearance to begin DMD and McCune-Albright Syndrome study applications by early 2027 (Jan-Apr).
YEAR
2027
2027 Clinical

Phase 2 Trial Starts

Atossa expects Phase 2 trials for cleared indications to begin during 2027; timing and sites to be announced.
Q2
2027
Q2 2027 Clinical

EVANGELINE Results

Topline EVANGELINE trial results expected in Q2 2027 (Apr-Jun); topline metrics and presentation/webcast details pending.
DEC
31
December 31, 2036 Regulatory

PRV award deadline

PRV award deadline 2036-12-31: FDA priority review voucher must be awarded by this date to qualify for CVR proceeds; proceeds capped at $50M.
DEC
31
December 31, 2036 Regulatory

Voucher Award Deadline

Priority review voucher must be awarded by Dec 31, 2036 (unless board extends); CVR holders get rights to 25% of net proceeds, capped $50M.
DEC
31
December 31, 2036 Financial

CVR Expiration Date

Atossa's contingent value rights expire if no qualifying rare pediatric disease priority review voucher is awarded by Dec 31, 2036.

Atossa Therapeutics has 7 upcoming scheduled events. The next event, "Data Presentations", is expected in December 2026. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the ATOS stock price.

Short Interest History

Last 12 Months

Short interest in Atossa Therapeutics (ATOS) currently stands at 526.8 thousand shares, down 22.9% from the previous reporting period, representing 5.4% of the float. Since the latest stock split, short interest has increased by 45.9%, measured from February 2026.

Days to Cover History

Last 12 Months

Days to cover for Atossa Therapeutics (ATOS) currently stands at 7.6 days, up 29.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 147.2%. Across the settlements charted above, it has ranged from 1.3 to 16.2 days.

ATOS Company Profile & Sector Positioning

Atossa Therapeutics (ATOS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ATOS often look at related companies in the same sector, including Lipocine Inc. (LPCN), Cocrystal Pharma, Inc. (COCP), IGC Pharma, Inc. (IGC), Estrella Immunopharma, Inc. (ESLA), and Cel-Sci Corporation (CVM). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ATOS's relative position within its industry.

Frequently Asked Questions

The current stock price of Atossa Therapeutics (ATOS) is $1.65 in after-hours trading as of November 20, 2026.

The market cap of Atossa Therapeutics (ATOS) is approximately $16.5M. Learn more about what market capitalization means .

The FY2025 net income of Atossa Therapeutics (ATOS) is -$34.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Atossa Therapeutics (ATOS) is -$4.04 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Atossa Therapeutics (ATOS) is -$29.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Atossa Therapeutics (ATOS), current assets divided by current liabilities, was 5.53 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Atossa Therapeutics (ATOS) is -$37.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops investigational medicines in oncology and other areas of significant unmet medical need. Its lead product candidate, (Z)-Endoxifen, is being studied across multiple breast cancer settings and in selected rare and serious diseases.

Atossa describes (Z)-Endoxifen as a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with activity across several mechanisms of interest. The company is developing a proprietary oral formulation designed to target estrogen receptors and inhibit protein kinase C beta 1 (PKCβ1). (Z)-Endoxifen is investigational and not approved for any indication.

Company disclosures state that (Z)-Endoxifen is in development for metastatic breast cancer, neoadjuvant treatment of ER+/HER2- breast cancer in premenopausal women, breast cancer risk reduction including strategies targeting mammographic breast density, and hormone receptor–positive ductal carcinoma in situ (DCIS) through the RECAST platform trial.

Yes. Atossa has reported that the FDA granted Rare Pediatric Disease designation to (Z)-Endoxifen for Duchenne Muscular Dystrophy and has highlighted scientific work on Duchenne carrier–associated pathologies. A joint AI-driven study with Insilico Medicine also identified (Z)-Endoxifen as a potential therapeutic candidate for glioblastoma multiforme.

Based on the company’s press releases and SEC filings, Atossa is a clinical-stage company and does not report any approved products. (Z)-Endoxifen is described as an investigational therapy that is not approved for any indication.

Atossa reports a growing global intellectual property portfolio that includes multiple issued U.S. patents and pending applications worldwide. These patents cover enteric oral formulations of highly pure (Z)-Endoxifen, methods of making and using endoxifen, stable crystalline forms, and various sustained-release and enteric dosage forms intended to provide sustained systemic exposure.

RECAST DCIS is a multi-arm, Phase 2 platform trial sponsored by Quantum Leap Healthcare Collaborative that evaluates endocrine therapies in hormone receptor–positive ductal carcinoma in situ. Atossa’s investigational agent (Z)-Endoxifen is one of the novel endocrine therapies being studied to determine which patients may be suitable for active surveillance instead of surgery, using imaging and biomarker endpoints.

Atossa has described several FDA interactions, including a Type C meeting to discuss expedited development pathways for (Z)-Endoxifen across metastatic, neoadjuvant, and risk-reduction breast cancer settings, and an FDA “Study May Proceed” letter for an IND covering a metastatic ER+/HER2- breast cancer study. The company also references regulatory strategy work for low-dose (Z)-Endoxifen in breast cancer risk reduction.

Atossa states that its common stock trades on Nasdaq under the ticker symbol ATOS.